QGEN: Three White Soldiers detected on 21 Oct 2026

QGEN is forming a three white soldiers pattern at 48.90, up 7.61% in one week and 20.53% in three months. The pattern structure scores 11.25/15, breakout scores 10.4/13, and volume 12/12—excellent relative volume at 3.77x average despite only moderate overall pattern quality (75.65/98). RSI is overbought at 70.43, and the stock sits 51.67% above its 52-week low. Key resistance is 50.82; a confirmed breakout targets 51.56 conservatively with 61.4% historical win probability. Support invalidates at 41.74.

On October 20, 2026, Swedish investment firm EQT is reportedly close to finalizing an acquisition deal for Qiagen, with the company's board set to review a binding offer exceeding $50 per share. U.S.-based private equity firm KKR has submitted a competing bid, fueling a notable rally in Qiagen's shares. This acquisition activity explains the recent surge: On October 02, 2026, Qiagen shares jumped 7.3% following reports that negotiations with a U.S.-listed molecular testing company have advanced toward a potential acquisition at a realistic premium. Operationally, Qiagen reported second-quarter 2026 results on August 5, delivering net sales of $535 million flat year-on-year but ahead of guidance, with adjusted diluted EPS reaching $0.62, topping the outlook of at least $0.60. On October 06, 2026, Qiagen unveiled new artificial intelligence features, introducing IPA Investigator, an AI-driven research assistant integrated into the QIAGEN Ingenuity Pathway Analysis platform.

A successful breakout above the 50.82 resistance would target 51.56, implying roughly 1.4% upside from current levels—modest but aligned with the pattern's 61.4% win probability. Volume confirmation is strong at 3.77x average, supporting the breakout thesis. The three white soldiers pattern typically precedes continuation moves in established uptrends; here, the healthcare sector regime is bullish (0.9) and broad market regime is highly bullish (0.95). Invalidation occurs decisively below 41.74, representing a 14.7% downside risk. The measured move suggests traders should expect resistance near 51.56 before any larger move.

Overbought RSI at 70.43 signals potential near-term pullback risk. The conservative target of 51.56 is only 1.4% above current price—limited margin of safety if the acquisition deal fails or bidders withdraw. Acquisition risk is material: The board is scheduled to meet this week to consider an offer exceeding $50 per share, with competing bids from KKR adding competitive tension. Immigration testing headwinds persist: QuantiFERON sales declined 5% in Q1 2026 mainly due to significant decline in immigration testing demand in the United States and the Middle East. Beta of 0.9 provides some downside protection, but elevated 20-day volatility at 37% suggests headline risk around deal announcements or rejections.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.